866-997-4948(US-Canada Toll Free)

Anal Cancer - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Aug 2016

Category :

Cancer

No. of Pages : 115 Pages

Anal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Directs, Anal Cancer - Pipeline Review, H2 2016, provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anal Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Anal Cancer - Overview 8
Pipeline Products for Anal Cancer - Comparative Analysis 9
Anal Cancer - Therapeutics under Development by Companies 10
Anal Cancer - Therapeutics under Investigation by Universities/Institutes 11
Anal Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Anal Cancer - Products under Development by Companies 14
Anal Cancer - Products under Investigation by Universities/Institutes 15
Anal Cancer - Companies Involved in Therapeutics Development 16
Advaxis, Inc. 16
Amgen Inc. 17
Cell Medica Limited 18
Eli Lilly and Company 19
Genticel S.A. 20
ISA Pharmaceuticals B.V. 21
Novartis AG 22
Ono Pharmaceutical Co., Ltd. 23
Oryx GmbH & Co. KG 24
PDS Biotechnology Corporation 25
Sun Pharma Advanced Research Company Ltd. 26
Taiwan Liposome Company, Ltd. 27
Anal Cancer - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
axalimogene filolisbac - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
CMD-004 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
GTL-001 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ISA-101 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
nivolumab - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
paclitaxel albumin free - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
panitumumab - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
PDR-001 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
PDS-0101A - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
prexasertib - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
TLC-388 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Vicoryx - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Anal Cancer - Dormant Projects 103
Anal Cancer - Product Development Milestones 104
Featured News & Press Releases 104
Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer 104
Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer 104
Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac 106
Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer 106
Dec 07, 2015: ISA Pharmaceuticals ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab 106
Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold 107
Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer 108
Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer 108
Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience 109
Sep 16, 2013: ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia 109
Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV 110
Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV 111
Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy 111
Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer 112
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables
Number of Products under Development for Anal Cancer, H2 2016 8
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Anal Cancer - Pipeline by Advaxis, Inc., H2 2016 16
Anal Cancer - Pipeline by Amgen Inc., H2 2016 17
Anal Cancer - Pipeline by Cell Medica Limited, H2 2016 18
Anal Cancer - Pipeline by Eli Lilly and Company, H2 2016 19
Anal Cancer - Pipeline by Genticel S.A., H2 2016 20
Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016 21
Anal Cancer - Pipeline by Novartis AG, H2 2016 22
Anal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 23
Anal Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016 24
Anal Cancer - Pipeline by PDS Biotechnology Corporation, H2 2016 25
Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 26
Anal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Anal Cancer - Dormant Projects, H2 2016 103

List of Figures
Number of Products under Development for Anal Cancer, H2 2016 8
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 12
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Targets, H2 2016 29
Number of Products by Stage and Targets, H2 2016 29
Number of Products by Mechanism of Actions, H2 2016 31
Number of Products by Stage and Mechanism of Actions, H2 2016 31
Number of Products by Routes of Administration, H2 2016 33
Number of Products by Stage and Routes of Administration, H2 2016 33
Number of Products by Molecule Types, H2 2016 35
Number of Products by Stage and Molecule Types, H2 2016 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *